Infectious Disease

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children: Which Children Benefit from Which Treatment? (MEASURE Trial)

Posted on by Jodi Snare

Page last updated March 12, 2026

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement, Clinical Research Collaboration Agreement
Principal Investigator: Nader Shaikh
Institution: University of Pittsburgh
PCORnet® Network Partner: PaTH
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2026 – 2032
Therapeutic Area: Infectious Disease
Status: Unknown Status

Research Question(s): Which children benefit from which treatment for sinus and ear infections?

Comparing Two Durations of Antibiotic Treatment for Children Hospitalized with Common Infections

Posted on by Jodi Snare

Page last updated March 12, 2026

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Sunitha Kaiser and Katherine Auger
Institution: University of California, San Francisco
PCORnet® Network Partner: REACHnet
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2025 – 2032
Participating PCORnet® Clinical Research Networks: GPC, OneFlorida+, PaTH, PEDSnet, REACHnet, STAR
Therapeutic Area: Infectious Disease
Status: Enrolling by invitation

Research Question(s):
For children hospitalized with pneumonia, skin infections, or urinary infections, do they recover better and have fewer side effects with a 5-day course of antibiotics, or a 10-day course of antibiotics?

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/tazobactam or Meropenem

Posted on by Jodi Snare

Page last updated February 4, 2026

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement, Clinical Research Collaboration Agreement
Principal Investigator: Daniel Freilich
Institution: Other
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2026 – 2029
Participating PCORnet® Clinical Research Networks: ADVANCE, GPC, INSIGHT, OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area: Infectious Disease; Nephrology
Status: Not yet recruiting

Research Question(s): 1) In hospitalized patients with severe infections, does the antibiotic combination workhorse, vancomycin and piperacillin/tazobactam (VPT), cause more kidney injury than another standard antibiotic combination, vancomycin and meropenem (VM), and 2) what is VPT's relative impact on other patient centric outcomes such as mortality, other kidney effects, hospital length of stay, readmissions, complications, and quality of life.

Advancing Public Health Use of Electronic Health Record Data

Posted on by Jodi Snare

Page last updated February 4, 2026

Study Design: Other, Data Science
PCORnet Infrastructure: Common Data Model (CDM), Patient partners or engagement
Principal Investigators: Jason P. Block and Tom Carton
Institution: Other
Funder: CDC
Funding Date: 2024
Study Duration: 2024 – 2025
Participating PCORnet® Clinical Research Networks: ADVANCE, GPC, INSIGHT, OneFlorida+, PaTH, PEDSnet, REACHnet, STAR
Therapeutic Area: Infectious Disease
Condition: Other; Public health surveillance across COVID-19, influenza and select chronic diseases and other infectious diseases
Status: Active, not recruiting

Research Question(s):

How can we use nationally distributed healthcare data infrastructure to (1) improve the capacity of data and information systems to conduct monitoring and surveillance and (2) increase the capability to use data to inform public health decision-making and support evidence-based practices and policies?

Primary Publication(s):

Zhang, Y., Romieu-Hernandez, A., Boehmer, T.K. et al. Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults. BMC Infect Dis 24, 181 (2024). https://doi.org/10.1186/s12879-024-09076-8

Jackson SL, Lekiachvili A, Block JP, et al. Preventive Service Usage and New Chronic Disease Diagnoses: Using PCORnet Data to Identify Emerging Trends, United States, 2018-2022. Prev Chronic Dis. 2024 Jul 3;21:E49. doi: 10.5888/pcd21.230415

Ghildayal N, Nagavedu K, Wiltz JL, et al. Public Health Surveillance in Electronic Health Records: Lessons From PCORnet. Prev Chronic Dis. 2024 Jul 11;21:E51. doi: 10.5888/pcd21.230417

HERO-TOGETHER: A Safety Surveillance Study of Post- Vaccination Events of Interest among People Vaccinated Against COVID-19

Posted on by Jodi Snare

Page last updated September 2, 2025

ClinicalTrials.gov#: NCT04342806
Study Design: Prospective Observational Study
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Emily O'Brien
Institution: Duke Clinical Research Institute
PCORnet® Network Partner: The Coordinating Center for PCORnet®
Funder: Pfizer
Funding Date: 2020
Study Duration: 2020 – 2022
Participating PCORnet® Clinical Research Networks: GPC, OneFlorida+, PaTH, REACHnet, STAR, The Coordinating Center for PCORnet®
Therapeutic Area: Infectious Disease
Status: Completed

Research Question(s): Can a research registry of people working in healthcare help to answer important questions about the COVID-19 pandemic on medications, vaccines and healthcare worker well-being?

Understanding the Short- and Long-term Effects of Disasters and other Big Events on the Overdose Crisis

Posted on by Jodi Snare

Page last updated December 15, 2025

Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Magdalena Cerdá
Institution: New York University Langone Health
PCORnet® Network Partner: INSIGHT
Funder: NIDA
Funding Date: 2023
Study Duration: 2023 – 2028
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, OneFlorida+, PaTH, PEDSnet, REACHnet, STAR
Therapeutic Area: Infectious Disease
Condition: COVID-19, Opioid Use
Population: 18 Years and older (Adult, Older Adult )
Status: Active, not recruiting

Research Question(s):

  1. Did a community rise in COVID-19 hospitalizations and deaths contribute to an increase in the risk of overdose among PCORnet patients?
  2. What role did public health and economic policies enacted during the COVID-19 pandemic play in explaining whether a rise in community COVID-19 burden contributed to a rise in overdose?
  3. Did the impact of the COVID-19 pandemic on overdose depend on the socioeconomic, social, and policy characteristics the community had in place prior to the pandemic?

HERO Registry & Trial: Healthcare Worker Exposure Response and Outcomes

Posted on by Jodi Snare

Page last updated October 29, 2025

Study Website: HERO Research Program
ClinicalTrials.gov#: NCT04342806
Study Design: Other, Registry and Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Adrian Hernandez
Institution: Duke Clinical Research Institute
PCORnet® Network Partner: The Coordinating Center for PCORnet®
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2020
Study Duration: 2020 – 2022
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, OneFlorida+, PaTH, PEDSnet, REACHnet, STAR
Therapeutic Area: Infectious Disease
Condition: Health Care Worker (HCW); COVID-19
Age Range: 18 Years and older (Adult, Older Adult)
Status: Completed

Research Question(s): Can a research registry of people working in healthcare help to answer important questions about the COVID-19 pandemic on medications, vaccines and healthcare worker well-being?

Primary Publication(s):

Friedland A, Hernandez AF, Anstrom KJ, et al. Design of healthcare worker exposure response and outcomes (HERO) research platform. Contemp Clin Trials, 2021; 109:106525. doi.org/10.1016/j.cct.2021.106525

Naggie S, Milstone A, Castro M, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ). Medrxiv, 2021. doi.org/10.1101/2021.08.19.21262275

The RECOVER Post-Acute Sequelae of SARS-CoV-2 (PASC) Electronic Health Record (EHR) Cohort Study

Posted on by Jodi Snare

Page last updated February 4, 2026

Study Website: RECOVERCOVID
Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Christopher Forrest, Charles Bailey and Grace Lee
Institution: The Children's Hospital of Philadelphia
PCORnet® Network Partner: PEDSnet
Funder: NIH
Funding Date: 2021
Study Duration: 2021 - 2025
Participating PCORnet® Clinical Research Networks: ADVANCE, GPC, PaTH, PEDSnet, STAR
Therapeutic Area: Infectious Disease
Condition: COVID-19; SARS-CoV-2 Infection
Age Range: Pediatrics 21 years and younger
Status: Active, not recruiting

Research Question(s):

  1. What are the long term health effects of COVID-19 after a person has recovered from infection?
  2. How can we better detect, predict, treat these health effects and prevent future infection?

Primary Publication(s):

Forrest CB, Burrows EK, Mejias A, et al. Severity of Acute COVID-19 in Children <18 Years Old March 2020 to December 2021. Pediatrics. 2022 Apr 1;149(4):e2021055765. doi:10.1542/peds.2021-055765

Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr. 2022;176(10):1000. doi:10.1001/jamapediatrics.2022.2800

Bose-Brill S, Hirabayashi K, Schwimmer E, et al; Researching COVID to Enhance Recovery consortium. Pediatric nirmatrelvir/ritonavir prescribing patterns during the COVID-19 pandemic. Hosp Pediatr. 2024;14(8):e341-e348. doi:10.1542/hpeds.2023-007132

PCORnet® Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults (PCORnetPASC)

Posted on by Jodi Snare

Page last updated October 29, 2025

Study Website: RECOVERCOVID
ClinicalTrials.gov#: NCT05292274
Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB
Principal Investigator: Rainu Kaushal
Institution: Weill Cornell Medicine
PCORnet® Network Partner: INSIGHT
Funder: NIH
Funding Date: 2022
Study Duration: 2022 - 2025
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area: Infectious Disease
Condition: COVID-19; SARS CoV 2 Infection
Age Range: 18 Years and older (Adult, Older Adult)
Status: Active, not recruiting

Research Question(s):

  1. What are the long term health effects of COVID-19 after a person has recovered from infection?
  2. How can we better detect, predict, and treat these health effects and prevent future infection?

Primary Publication(s):

Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of select new symptoms and conditions among person aged younger than 20 years and 20 years or older at 31 to 150 days after testing positive or negative for SARS-CoV-2. JAMA Netw Open. 2022;5(2):e2147053. doi.org/10.1001/jamanetworkopen.2021.47053

Comparing patient-reported impact of COVID-19 shelter-in-place policies and access to containment and mitigation strategies, overall and in vulnerable populations

Posted on by Jodi Snare

Page last updated October 29, 2025

Study Website: COVID-19 Citizen Science
ClinicalTrials.gov#: NCT05548803
Study Design: Prospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Mark Pletcher
Institution: University of California, San Francisco
PCORnet® Network Partner: REACHnet
Funder: Patient-Centered Outcomes Research Institute (PCORI); (project webpage)
Funding Date: 2020
Study Duration: 2020 – 2023
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, REACHnet
Therapeutic Area: Infectious Disease
Condition: COVID-19
Age Range: 18 Years and older (Adult, Older Adult)
Status: Completed

Research Question(s):

  1. What is the comparative impact of different shelter-in-place/reopening policies, overall and in vulnerable populations, on patient-reported financial insecurity, mental health, and other subjective outcomes important to patients?
  2. What is the comparative effectiveness of county-level containment and mitigation strategies at achieving timely access to testing, healthcare, information, and contact tracing, overall and in vulnerable populations?
  3. What is the comparative accuracy of different algorithms designed to predict risk of infection and severe COVID-19 among patients with symptoms, overall and in vulnerable populations?

Primary Publication(s):

Beatty AL, Peyser ND, Butcher XE, et al. The COVID-19 citizen science study: protocol for a longitudinal digital health cohort. JMIR Res Protoc, 2021; 10(8):e28169. doi:10.2196/28169